Tony Romagnino

Market Research Analyst
Cardiology
Clarity Pharmaceuticals
Australia

Business Expert Cardiology
Biography

Tony is an Alternate Director to Matt Harris. As a former General Manager of Technology Commercialisation at NewSouth Innovations (NSi), his team quadrupled the licensing, research and commercial income at UNSW; closed one of the single largest licensing deals in the history of UNSW in nuclear medicine; and managed eight spin out companies. He was also the UNSW/NSi Investment Manager at Uniseed, a university-based venture capital firm managing $60m in pre-seed investments. Previous to UNSW, Mr Romagnino worked with the Drug Distribution Network, a US-based third party logistics company specialising in marketed pharmaceuticals. His experience in manufacturing, distribution and marketing enabled him to build relationships at every level of the US pharmaceutical supply chain. Tony is a true business development professional with contacts in well over 1000 international pharmaceutical and biotech companies and he has a unique, worldwide view on technology development. Mr Romagnino is currently the principal and co-founder of TM Ventures. Tony is an Alternate Director to Matt Harris. As a former General Manager of Technology Commercialisation at NewSouth Innovations (NSi), his team quadrupled the licensing, research and commercial income at UNSW; closed one of the single largest licensing deals in the history of UNSW in nuclear medicine; and managed eight spin out companies. He was also the UNSW/NSi Investment Manager at Uniseed, a university-based venture capital firm managing $60m in pre-seed investments. Previous to UNSW, Mr Romagnino worked with the Drug Distribution Network, a US-based third party logistics company specialising in marketed pharmaceuticals. His experience in manufacturing, distribution and marketing enabled him to build relationships at every level of the US pharmaceutical supply chain. Tony is a true business development professional with contacts in well over 1000 international pharmaceutical and biotech companies and he has a unique, worldwide view on technology development. Mr Romagnino is currently the principal and co-founder of TM Ventures.

Research Intrest

Radiochemist